Gene Expression and Resistance to Glucocorticoid-Induced Apoptosis in Acute Lymphoblastic Leukemia: A Brief Review and Update.
Glucocorticoids
RelA
acute lymphoblastic leukemia
apoptosis
gene expression
glucocorticoid-induced apoptosis resistance
prednisolone
Journal
Current drug research reviews
ISSN: 2589-9783
Titre abrégé: Curr Drug Res Rev
Pays: United Arab Emirates
ID NLM: 101735701
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
10
2019
revised:
29
12
2019
accepted:
23
01
2020
pubmed:
23
2
2020
medline:
15
10
2021
entrez:
21
2
2020
Statut:
ppublish
Résumé
Resistance to glucocorticoid (GC)-induced apoptosis in Acute Lymphoblastic Leukemia (ALL), is considered one of the major prognostic factors for the disease. Prednisolone is a corticosteroid and one of the most important agents in the treatment of acute lymphoblastic leukemia. The mechanics of GC resistance are largely unknown and intense ongoing research focuses on this topic. The aim of the present study is to review some aspects of GC resistance in ALL, and in particular of Prednisolone, with emphasis on previous and present knowledge on gene expression and signaling pathways playing a role in the phenomenon. An electronic literature search was conducted by the authors from 1994 to June 2019. Original articles and systematic reviews selected, and the titles and abstracts of papers screened to determine whether they met the eligibility criteria, and full texts of the selected articles were retrieved. Identification of gene targets responsible for glucocorticoid resistance may allow discovery of drugs, which in combination with glucocorticoids may increase the effectiveness of anti-leukemia therapies. The inherent plasticity of clinically evolving cancer justifies approaches to characterize and prevent undesirable activation of early oncogenic pathways. Study of the pattern of intracellular signal pathway activation by anticancer drugs can lead to development of efficient treatment strategies by reducing detrimental secondary effects.
Sections du résumé
BACKGROUND
BACKGROUND
Resistance to glucocorticoid (GC)-induced apoptosis in Acute Lymphoblastic Leukemia (ALL), is considered one of the major prognostic factors for the disease. Prednisolone is a corticosteroid and one of the most important agents in the treatment of acute lymphoblastic leukemia. The mechanics of GC resistance are largely unknown and intense ongoing research focuses on this topic.
AIM
OBJECTIVE
The aim of the present study is to review some aspects of GC resistance in ALL, and in particular of Prednisolone, with emphasis on previous and present knowledge on gene expression and signaling pathways playing a role in the phenomenon.
METHODS
METHODS
An electronic literature search was conducted by the authors from 1994 to June 2019. Original articles and systematic reviews selected, and the titles and abstracts of papers screened to determine whether they met the eligibility criteria, and full texts of the selected articles were retrieved.
RESULTS
RESULTS
Identification of gene targets responsible for glucocorticoid resistance may allow discovery of drugs, which in combination with glucocorticoids may increase the effectiveness of anti-leukemia therapies. The inherent plasticity of clinically evolving cancer justifies approaches to characterize and prevent undesirable activation of early oncogenic pathways.
CONCLUSION
CONCLUSIONS
Study of the pattern of intracellular signal pathway activation by anticancer drugs can lead to development of efficient treatment strategies by reducing detrimental secondary effects.
Identifiants
pubmed: 32077838
pii: CDRR-EPUB-104688
doi: 10.2174/2589977512666200220122650
doi:
Substances chimiques
Antineoplastic Agents
0
Glucocorticoids
0
Prednisolone
9PHQ9Y1OLM
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
131-149Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.